The multitargeted effects of T4OL—simultaneously reducing inflammation (NF-κB1/IL-6), hypoxia (HIF-1α), and fibrosis (TGF-β1/MMP1)—make it a promising candidate for ALD treatment, particularly in alcoholic-steatohepatitis and early fibrosis stages. Here, MMP1 is linked to alcoholic fatty liver disease.